Digital symptom monitoring is valued by radiotherapy patients, but stress reduction remains unproven

Among 183 radiotherapy patients, 36.6% perceived less treatment-related stress from electronic symptom monitoring, and 68.4% wanted to continue using the platform.

KEY POINTS

  • This prospective observational study evaluated electronic patient-reported outcome (ePRO) monitoring during routine radiotherapy at University Hospital Bonn, Germany. Of 303 patients offered access, 256 registered, and 183 who used the platform and completed a post-treatment experience questionnaire were included in the final analysis. Participants had prostate cancer (n=77), breast cancer (n=68), or CNS tumors (n=38). Median age was 65 years, and median treatment duration was 20 fractions.
  • The intervention combined structured weekly assessments with optional interactive features. Patients used the Noona digital platform to complete EORTC QLQ-C30 questionnaires and disease-specific quality-of-life modules. Additional functions included symptom diaries, predefined alerts for clinically significant symptoms, and secure communication with the clinical care team. Among participants, 89.1% used symptom reporting, 41.0% used secure communication, and 29.0% used the symptom diary. The most common self-reported engagement frequency was weekly (56.3%), while 22.4% used the platform at least daily.
  • Only a minority reported perceived stress reduction, although most wanted continued access. Overall, 67/183 patients (36.6%) agreed or strongly agreed that using the platform reduced treatment-related stress, while 125/183 (68.4%) expressed willingness to continue using it after radiotherapy. These were subjective questionnaire responses obtained at treatment completion, not changes measured using a validated psychological stress scale. Actual platform use during follow-up was not assessed.
  • Daily engagement was associated with greater perceived benefit than weekly use. In multivariable ordinal regression, patients reporting daily use had higher odds of stronger agreement that the platform reduced treatment-related stress (OR 2.24, 95% CI 1.07–4.68; p=0.033). Monthly users had lower odds of perceived stress reduction (OR 0.31, 95% CI 0.15–0.63; p=0.001) and lower willingness to continue using the platform (OR 0.37, 95% CI 0.18–0.75; p=0.006). However, these associations cannot establish whether greater engagement produced perceived benefit or whether patients who found the system useful engaged more often.
  • Bidirectional communication may contribute to sustained engagement. Patients using the secure communication function had numerically higher odds of intending continued platform use (OR 1.81, 95% CI 0.99–3.30; p=0.055), although the association did not reach conventional statistical significance. Each additional radiotherapy fraction was associated with slightly lower odds of perceived stress reduction (OR 0.96 per fraction, 95% CI 0.93–1.00; p=0.035). Demographic characteristics, disease stage, and diagnosis did not emerge as significant predictors of perceived benefit.
  • The study assessed perceptions rather than demonstrated improvements in clinical outcomes. There was no control group receiving radiotherapy without ePRO monitoring, and no validated baseline or follow-up measure of stress reduction was included in the analysis. The experience questionnaire was developed for the study without formal psychometric validation, while engagement frequency was self-reported rather than verified against platform analytics. Patients who declined registration, did not engage, discontinued use, or failed to complete the questionnaire were not represented.
  • The findings identify implementation priorities but do not validate a specific monitoring frequency. Only 183 of 303 patients offered the platform contributed to the final analysis, potentially enriching the sample for digitally confident or satisfied users. Differences in language proficiency, access to technology, and patient expectations were incompletely assessed. The study therefore supports further investigation of interactive, clinician-integrated ePRO pathways rather than establishing that daily digital monitoring independently improves psychological well-being.

CLINICAL TAKEAWAY

Digital symptom-monitoring platforms may provide patients with value beyond data collection, particularly when they support communication with their treating team. However, this observational study measured perceived benefit and willingness to continue use rather than validated changes in stress, quality of life, or clinical outcomes. Effective implementation will require attention to patient selection, accessibility, and whether reported symptoms lead to meaningful clinical responses.

SOURCE

Technical Innovations & Patient Support in Radiation Oncology

Browse more research Suggest a correction